I guess big pharma must feel it hasn't done enough damage to the people, why in the world...ohhhh $$$ is involved.
(credits: Dr John Campbell) ⁣https://www.youtube.com/watch?v=uVd6IonyI0Y
TGA to stop reporting myocarditisTo donate to the work of campbellteaching around the world,https://www.paypal.com/donate/....?hosted_button_id=XS is reported in around 2 in every 100,000 of those who receive Spikevax (Moderna).As reporting rates of myocarditis and pericarditis following vaccination are very stable, we will not include this section in future COVID-19 vaccine safety reports. However, we continue to monitor and review these adverse effects and will communicate any updated safety advice if needed.https://www.tga.gov.au/news/co....vid-19-vaccine-safet course recommendationsCOVID-19 vaccination is recommended for all people aged 5 years or older to protect against COVID-19. For most people, a primary vaccination course consists of 2 doses.Adverse reactions, TGA dataOne adverse event report per 490 doses given, 0.2039%In Western Australiahttps://www.health.wa.gov.au/~..../media/Corp/Document adverse events (97%) occurred after a COVID-19 vaccine21 times more common than ‘conventional’ vaccinesSwiss dataMyocardial Injury after COVID-19 mRNA-1273 Booster Vaccination https://onlinelibrary.wiley.co....m/doi/epdf/10.1002/e vaccine-associated myocardial injury was adjudicated in 22 participants (2.8%).(N = 777 per group)One in 35 recipients (2.8%) had vaccine-associated myocardial injuryMatched controls, elevated high-sensitivity cardiac troponin T concentrationSignificantly higher in post vaccination group p less than 0.001Thai studyCardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescentshttps://www.ncbi.nlm.nih.gov/p....mc/articles/PMC94140 BNT162b2, 2nd dose, Thai adolescents, aged 13–18 years, n = 314Seven participants (2.33%) exhibited at least one elevated cardiac biomarkerMyopericarditis was confirmed in one patient after vaccination. Two patients had suspected pericarditisFour patients had suspected subclinical myocarditisHence, adolescents receiving mRNA vaccines should be monitored for cardiovascular side effects.Israeli studyA prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy personshttps://pubmed.ncbi.nlm.nih.gov/36097844/Incidence of myocardial injury after fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech)N = 324Reported vaccine-related adverse reactionsChest pain in 12 (3.7%)Palpitations in 7 (2.16%)Vaccine-related myocardial injury in two (0.62%)https://www.gov.uk/government/....publications/myocard vaccinationAs of 23 November 2022, following Pfizer/BioNTech851 reports of myocarditis and 579 reports of pericarditisTotal of 1,430Following Moderna vaccine251 reports of myocarditis149 reports of pericarditisTotal of 1,530As of 23 November 2022, myocarditis following monovalent Pfizer/BioNTech was 10 reports per million doses; If there is a suspicion of myocarditis or pericarditis, initial investigations should be:12 lead electrocardiogram (ECG)inflammatory blood markers (C-reactive protein (CRP), full blood count (FBC) and erythrocyte sedimentation rate (ESR)TroponinIf there is no evidence of ongoing myocarditis, vaccination may be considered with the Pfizer/BioNTech (Cominarty) vaccine from 12 weeks after their last dose if further doses are due. If the individual feels well after receiving their COVID-19 vaccination, then there is no need to pre-emptively restrict physical activity post vaccination and individuals can continue with their pre-existing level of physical activity.